Scivision Biotech Stock Current Liabilities
1786 Stock | TWD 93.40 3.80 3.91% |
SciVision Biotech fundamentals help investors to digest information that contributes to SciVision Biotech's financial success or failures. It also enables traders to predict the movement of SciVision Stock. The fundamental analysis module provides a way to measure SciVision Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to SciVision Biotech stock.
SciVision |
SciVision Biotech Company Current Liabilities Analysis
SciVision Biotech's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current SciVision Biotech Current Liabilities | 98 M |
Most of SciVision Biotech's fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, SciVision Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
Competition |
In accordance with the recently published financial statements, SciVision Biotech has a Current Liabilities of 98 M. This is 94.41% lower than that of the Healthcare sector and 82.43% lower than that of the Medical Instruments & Supplies industry. The current liabilities for all Taiwan stocks is 98.76% higher than that of the company.
Did you try this?
Run Portfolio Analyzer Now
Portfolio AnalyzerPortfolio analysis module that provides access to portfolio diagnostics and optimization engine |
All Next | Launch Module |
SciVision Fundamentals
Return On Equity | 0.0952 | |||
Return On Asset | 0.0331 | |||
Profit Margin | 0.26 % | |||
Operating Margin | 0.23 % | |||
Current Valuation | 3.06 B | |||
Shares Outstanding | 66.19 M | |||
Shares Owned By Insiders | 38.09 % | |||
Shares Owned By Institutions | 0.09 % | |||
Price To Earning | 46.92 X | |||
Price To Book | 2.47 X | |||
Price To Sales | 6.56 X | |||
Revenue | 505.54 M | |||
Gross Profit | 341.84 M | |||
EBITDA | 177.14 M | |||
Net Income | 101.72 M | |||
Cash And Equivalents | 508.81 M | |||
Cash Per Share | 8.76 X | |||
Total Debt | 300 M | |||
Debt To Equity | 22.50 % | |||
Current Ratio | 4.11 X | |||
Book Value Per Share | 22.18 X | |||
Cash Flow From Operations | 98.51 M | |||
Earnings Per Share | 2.07 X | |||
Number Of Employees | 11 | |||
Beta | 0.62 | |||
Market Capitalization | 3.92 B | |||
Total Asset | 2.26 B | |||
Retained Earnings | 32 M | |||
Working Capital | 559 M | |||
Current Asset | 657 M | |||
Current Liabilities | 98 M | |||
Z Score | 7.8 | |||
Annual Yield | 0.02 % | |||
Net Asset | 2.26 B | |||
Last Dividend Paid | 1.42 |
About SciVision Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze SciVision Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SciVision Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SciVision Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for SciVision Stock Analysis
When running SciVision Biotech's price analysis, check to measure SciVision Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SciVision Biotech is operating at the current time. Most of SciVision Biotech's value examination focuses on studying past and present price action to predict the probability of SciVision Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SciVision Biotech's price. Additionally, you may evaluate how the addition of SciVision Biotech to your portfolios can decrease your overall portfolio volatility.